Hepatology | 2021
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients
Abstract
Pangenotypic direct-acting antiviral (DAA) drugs have a hepatitis C (HCV) cure rate of >95% in almost all treated patients. When DAA treatment fails, retreatment must be guided by virus resistance profiles, and phase III trials have reported sustained virological responses (SVR) of 96-98% after a 12-week course of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX).